News
Innovators are using AI to bridge gaps in breast cancer care

AI is increasingly being leveraged to address challenges in breast cancer care, from a “second set of eyes” during screening to enabling more personalised treatments. Innovators say it can not only deliver better outcomes, but also make medicine more accurate and accessible.
Breast cancer is the leading cancer in women globally, affecting around two million women, or one in eight, every year.
Early detection is critical for improving survival rates, with over 90 per cent of women surviving for five years or more when the cancer is diagnosed in the early stages.
However, research has shown that between 20 and 40 per cent of cancers may be missed through routine 2D mammography alone, particularly among women with dense breast tissue, which makes tumours harder to detect without specialist diagnostic tools.
AI is increasingly being leveraged to address these challenges, from enhanced imaging interpretation and risk prediction to personalised diagnostics and treatment planning.
On World Cancer Day (February 4), the NHS announced a ‘world-leading’ trial to test how AI tools can be used to catch breast cancer cases earlier, with 700,000 women taking part at more than 30 breast clinics across England.
The EDITH trial (Early Detection using Information Technology in Health) is backed by £11 million of government support. It aims to double radiologist capacity, speed up results, and detect cancers earlier via algorithm‑based comparisons with historical imaging.
The technology will assist radiologists in identifying changes in breast tissue that show possible signs of cancer, enabling just one specialist to complete the same mammogram screening that would previously have required two to carry out the process safely and efficiently.
In a previous trial, involving 10,000 women receiving care through the NHS, an AI tool known as Mia identified small signs of breast cancer in 11 women which had been missed by doctors.
Announcing the EDITH pilot in February, Lucy Chappell, chief scientific adviser at the Department of Health and Social Care and CEO of the National Institute for Health Research, said the “landmark trial” could lead to a “significant step forward in the early detection of breast cancer”, offering women faster, more accurate diagnoses.
“A second set of eyes”
AI algorithms are now being widely used as “second readers” to analyse scans and flag abnormalities that might otherwise go unnoticed. Clinical trials in Europe and the US have demonstrated that AI-supported screening can increase detection rates while maintaining or reducing false positives.
A nationwide study in Germany, thought to be the first to use AI screening from the outset in a real-world setting, found that radiologists with access to AI technology had a 17.6 per cent higher rate of detection compared to the control group.
“The addition of AI has improved our ability to detect cancers years earlier, especially in women with dense breast tissue, where traditional mammography has limitations,” Dr Sean Raj, chief innovation officer at SimonMed Imaging, tells Femtech World.
Mammogram+, developed by SimonMed, integrates 3D mammography with FDA-cleared AI to generate up to 400 high-resolution images per scan, compared to just four in a standard 2D mammogram.
“The AI system in Mammogram+ acts as a second set of highly trained eyes, assisting radiologists in detecting potential malignancies,” Dr Raj explains.
“It works to analyse each image quickly and provide key data from a completely objective point of view, allowing our radiologists to build on perspectives they may not have had before.”
While the AI is enhancing its capability, human intelligence remains central to the programme’s efficacy.
“Our radiologists bring extensive expertise and clinical judgment, while AI provides a complementary, unbiased perspective,” Dr Raj adds.
“By working together, we achieve the best of both worlds, human experience combined with advanced computational analysis.”
While long-term outcome data is still being collected, SimonMed has observed promising early results from the implementation of Mammogram+, including increased confidence for radiologists interpreting images and patients receiving their results, he says.
Patients are also demonstrating higher levels of engagement in their care, which he puts down to the programme’s focus on delivering ‘clear, actionable results’.
Patients receive an easy-to-read report the same day, explaining breast density, personal risk score, and outlining a tailored action plan.
“We believe that when patients are provided with clear information about their breast health and a personal action plan outlining exactly what to do, they are more likely to take the next step,” he adds.
More personalised and effective treatments
Once a patient has been diagnosed with breast cancer, outcomes largely depend on having quick access to the most effective treatment.
But despite decades of advancements in the field, there are still a lot of unknowns when it comes to the question of which treatment a tumour will respond to.
“Part of the reason breast cancer is so difficult to treat is that no two tumours are alike. Even within a single tumour, cells can behave very differently, explained Wolfgang Hackl, translational oncology scientist and founder and CEO of Swiss startup OncoGenomX, in a recent editorial for Femtech World.
Hackl believes the decision lies in precision oncology, and with OncoGenomX, has developed a clinical decision support platform to personalise precision cancer treatment to enable individualised therapeutic decisions.
According to the company’s research, 56 per cent of women living with metastatic breast cancer are at risk of receiving suboptimal treatment compositions, leading to poorer clinical outcomes and avoidable cancer care costs.
OncoGenomX’s PredictionStar™ tool uses AI and machine learning algorithms to identify whether a certain therapy works in a particular tumour and finds the most effective treatment for each patient and their tumour. It has been found to reduce the over-treatment rate by at least 40 per cent, incurring a five-fold lower risk of cancer regrowth.
“PredictionStar takes away the uncertainty around breast cancer treatment decisions and increases the likelihood of opting for the most effective treatment combination without delay and without exposing the patient to the side effects of an ineffective treatment,” says Hackl.
AI and its role in the gender health gap
The potential of AI in healthcare extends far beyond breast cancer, with the potential to address other areas of medicine where women are underdiagnosed, undertreated and have poorer outcomes, such as cardiovascular care.
SimonMed has just launched a new AI-powered software that detects breast arterial calcifications (BAC), offering “enhanced care and a two-for-one mammogram”.
“Using the same screenings from the mammogram, we can detect the presence of BAC, providing dual insights into two of the biggest health risks for women, breast cancer and heart health, all without extra radiation or procedure time for the patient,” Dr Raj explains.
“For years, women have faced a gender health gap, affecting women’s access and affordability, misdiagnosis, and medical research bias.
“We’re excited by the possibility that AI can help us close that gap and improve health outcomes for women by having more accurate, faster tools for the detection and treatment and providing patients and their providers with more data and insights to make more informed decisions, sooner.”
He adds: “With the help of AI in women’s healthcare, like breast cancer detection, we will be able to improve health outcomes for women, making healthcare more accessible, affordable, and accurate.”
Urging caution – governance and collaboration
However, several experts and peer-reviewed papers have urged caution around the widespread use of AI, with risks including overdiagnosis, false positives, bias, and workflow disruption, highlighting the importance of regulatory oversight and ethical safeguards.
A review published earlier this year raised several concerns, including inconsistent performance, poor generalisability, lack of robust evidence frameworks, trust issues among clinicians, and gaps in legal and ethical governance.
The researchers concluded that more robust strategies are needed before AI can be scaled for routine use in breast cancer screening, making recommendations for a “comprehensive AI governance framework”.
“While AI has the potential to improve diagnostic accuracy and efficiency, its broader implications include promoting equitable health care delivery, strengthening patient trust, and supporting the ethical development of AI technologies,” the authors write.
“Policy makers, clinicians, and AI developers must work collaboratively to establish adaptable and transparent systems that prioritise patient safety and societal benefits.
“Future research should focus on real-world case studies, longitudinal assessments, and cross-disciplinary collaborations to effectively refine and implement these governance strategies.”
Menopause
Hormone therapy users report healthier lifestyles

Menopausal women using hormone therapy reported healthier diet, exercise and sleep habits than non-users in a study of more than 10,000 women.
The menopause transition is associated with a higher risk of chronic health conditions and symptoms including hot flushes and problems affecting the urinary and genital systems.
Hormone therapy is often used to manage these symptoms, but it remains unclear whether it affects health outcomes directly or indirectly through changes in health behaviours.
Previous research has produced mixed results, with some studies suggesting that postmenopausal women pay greater attention to maintaining a healthy lifestyle.
The cross-sectional analysis examined whether menopause status and hormone therapy use were linked to diet, physical activity and sleep duration.
A cross-sectional study assesses participants at one point in time. It can identify associations but cannot establish whether one factor directly caused another.
Diet, exercise and sleep are described as modifiable health behaviours because people may be able to change them to improve their health.
The researchers found that postmenopausal women who had never used hormone therapy reported eating less fruit and vegetables.
Women who had never used the treatment were also 19 per cent less likely to meet guidelines for muscle-strengthening activity.
Sleep duration was shorter among postmenopausal women who had never used hormone therapy.
Compared with premenopausal and perimenopausal women, the likelihood of meeting sleep guidelines was 14 per cent lower among never-users, 26 per cent lower among current users and 24 per cent lower among past users.
Perimenopause is the transitional period before menopause, when hormone levels and menstrual periods can change.
Researchers said these findings may be linked to higher levels of follicle-stimulating hormone among postmenopausal women who do not use hormone therapy.
They may also relate to lower levels of oestradiol, a form of oestrogen, which have previously been associated with poorer sleep.
Hot flushes and urogenital symptoms can also disrupt sleep, although hormone therapy may ease these symptoms.
Dr Stephanie Faubion, medical director for The Menopause Society, said: “This large observational study underscores that women who use hormone therapy tend to adopt overall healthier lifestyles.
“Although this association may partly reflect better symptom control enabling healthier behaviours, healthy-user bias is likely a significant contributor.
“Women who choose to use hormone therapy are often more proactive in their healthcare and may systematically differ from nonusers in socioeconomic resources, access to care, and health literacy.
“This largely explains why early observational studies of hormone therapy suggested cardiovascular benefits that were not confirmed in subsequent randomised, controlled trials.”
Ageing
Strength training may lower heart disease risk in women, study suggests

Women who do strength training may have a lower risk of major cardiovascular disease, particularly alongside aerobic activity, a study suggests.
Cardiovascular disease is the leading cause of death worldwide. Aerobic activities such as brisk walking, jogging, cycling and swimming are already established ways to help reduce the risk.
Strength or resistance training, also known as RT, is less established as a prevention strategy. It makes muscles work against a force and can involve body weight, free weights, resistance bands or machines.
Current US guidelines recommend at least two days of strength training and 150 minutes of moderate-to-vigorous aerobic activity each week.
They also recommend limiting sedentary behaviour, including prolonged television viewing, which is considered an independent risk factor for cardiovascular disease.
Dr Tianyue Zhang, lead study author and scientist in the department of nutrition at the Harvard T.H. Chan School of Public Health, said: “Despite its established health benefits, RT is often overlooked as a prevention strategy for CVD, and its impact on CVD risk, especially in middle-aged and older women, remains understudied.
“A key question is, how much does it add beyond aerobic activity alone?”
Researchers analysed data from 117,025 women participating in the Nurses’ Health Study and Nurses’ Health Study II.
The two groups had average starting ages of 66.8 and 48.1 years respectively.
The women reported their resistance training every four years, with exercises involving the arms and legs recorded separately.
Time spent watching television was used as the main measure of sedentary behaviour.
The researchers examined exercise and television-viewing habits alongside the incidence of major cardiovascular disease.
Major cardiovascular events included fatal or non-fatal heart attacks, strokes, coronary artery bypass surgery and percutaneous coronary intervention.
Coronary artery bypass surgery redirects blood around narrowed or blocked heart arteries. Percutaneous coronary intervention uses a small balloon, often followed by a stent, to open a narrowed artery.
Higher levels of strength training were associated with a lower risk of major cardiovascular disease, particularly heart attacks.
No statistically significant link with stroke was found when resistance exercise was considered separately.
Women completing at least two hours of strength training a week had a 20 per cent lower risk of major cardiovascular disease and a 44 per cent lower risk of heart attack than those doing none.
Each additional hour a week was associated with a five per cent lower risk of major cardiovascular disease and a 14 per cent lower risk of heart attack.
The associations weakened somewhat after researchers accounted for body mass index and conditions including diabetes, high blood pressure and high cholesterol, but remained clear.
Body mass index, or BMI, compares weight with height and is commonly used to assess whether someone is within a healthy weight range.
Strength training was also linked to additional benefits among women who did aerobic activity.
Women completing at least two hours of strength training and 150 minutes of aerobic activity each week had a 45 per cent lower risk of heart attack than those reporting no physical activity.
Women who met recommendations for strength training, aerobic activity and reduced television viewing had the lowest risks of major cardiovascular disease, heart attack and stroke compared with those who met some or none of the recommendations.
Zhang said: “These findings suggest that, within an already active population, RT is associated with additional reductions in CVD risk above and beyond overall aerobic activity.
“Alongside aerobic activity and reductions in sedentary behaviour, RT may be an important component of public health strategies for cardiovascular prevention in women.”
The study relied on participants reporting their own resistance training, meaning the data may not always have been precise.
Researchers also noted the possible influence of unmeasured factors and the limited diversity of participants.
They were unable to fully separate the effects of the type of resistance training performed from the overall amount completed.
Dr Harlan M. Krumholz, professor at Yale School of Medicine, said: “We have long encouraged resistance training, and this study provides strong evidence to reinforce that message.
“It should be included in a well-rounded health routine to support function and longevity.”
Pregnancy
Women with pre-eclampsia at increased risk of chronic kidney disease, study finds

Women who develop pre-eclampsia face a higher risk of chronic kidney disease and high blood pressure later in life, new research suggests.
The amount of protein found in the urine during pregnancy may help identify those at greatest risk of developing long-term health problems.
Pre-eclampsia usually involves high blood pressure and increased protein in the urine. Some women also experience severe headaches and changes to their vision.
The condition cannot be treated during pregnancy and, in some cases, labour must be induced early to protect both the woman and baby.
The study found that the condition may be linked to longer-term health problems.
Anne Høy Seemann Vestergaard, a medical doctor and PhD at the department of clinical medicine at Aarhus University, said: “What we can see is a clear association between pre-eclampsia and the development of high blood pressure, chronic kidney disease and cardiovascular disease later in life.”
The researchers found that the amount of protein passed in the urine during pregnancy was linked to the risk of developing chronic conditions after giving birth.
Protein in the urine can indicate that the kidneys are not filtering blood normally.
Vestergaard said: “The most surprising finding was how clearly the amount of protein in the urine during pre-eclampsia was linked to the risk of later high blood pressure and chronic kidney disease. Women with moderate to severe protein excretion had a higher risk of both conditions compared with women with low or no protein excretion.”
Among women with pre-eclampsia and moderate to severe levels of protein in the urine, around one in 20 developed chronic kidney disease within 10 years and around one in six developed high blood pressure.
Most women in the study did not develop long-term complications, but the researchers said the increased risk should still be taken seriously because the potential effects can be severe.
Vestergaard said: “At first glance, this may sound like a low number, but it represents a markedly increased risk when the groups are compared. In the group with pre-eclampsia and high levels of protein in the urine, around 1 in 20 women developed chronic kidney disease within ten years, including early stages of the disease, compared with around 1 in 100 in the group with lower or no protein excretion.”
She added: “That is a considerable number in light of the fact that chronic kidney disease is a potentially serious condition that can progress to kidney failure if isn’t diagnosed early.”
The findings suggest women who experience pre-eclampsia may benefit from more systematic monitoring after pregnancy.
Vestergaard said: “Our study suggests that these women may benefit from monitoring of blood pressure and kidney function after pregnancy.”
Menopause4 weeks agoPerimenopause misinformation ‘putting women at risk’
Entrepreneur3 weeks agoWomen’s Health Innovation Summit opens submissions for 2026 Innovation Showcase
Insight2 weeks agoBritish women among angriest in Europe, health survey reveals
News3 weeks agoWomen still being failed when they reach menopause, experts say
Menopause3 weeks agoSweden eyes domestic production of oestrogen patches amid menopause treatment shortage
News3 weeks agoThree menopause innovators shortlisted for Femtech World Award
News1 week agoFemtech World Awards 2026: Winners revealed
Menopause2 weeks agoApple Health adds menopause and perimenopause tracking














